NCT04370509 2025-11-19
Pembrolizumab With or Without Axitinib for Clear Cell Kidney Cancer in Patients Undergoing Surgery
University of California, San Francisco
Phase 2 Terminated
University of California, San Francisco
Institute of Cancer Research, United Kingdom
Incyte Corporation
Academic and Community Cancer Research United
University of Texas Southwestern Medical Center
Eli Lilly and Company